宁夏中科生物科技股份有限公司 关于召开2025年第三次临时股东会的通知 证券代码：600165 证券简称：ST 宁科 公告编号：2025-089 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2025 年 9 月 2 日14 点 30 分 召开地点：宁夏中科生物科技股份有限公司（以下简称：公司）会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 2 日 至2025 年 9 月 2 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 1 股东会召开日期：2025年9月2日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 (一) 股东会类型和届次 2025年第三次临时股东会 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次董事会应到董事 7 名，实到董事 7 名。 ● 本次董事会共三项议案，经审议全部获得通过。 一、董事会会议召开情况 证券代码：600165 股票简称：ST 宁科 公告编号：临 2025-087 宁夏中科生物科技股份有限公司 第九届董事会第四十四次会议决议公告 （一）本次董事会召开符合有关法律、行政法规、部门规章、规范性文件和 《宁夏中科生物科技股份有限公司章程》的规定。 （二）本次董事会通知于 2025 年 8 月 5 日以微信和电子邮件方式送达，会 议材料于 2025 年 8 月 12 日以电子邮件方式送达。 （三）本次董事会于 2025 年 8 月 15 日上午 10:00 以现场结合通讯方式召开。 （四）本次董事会应到董事 7 名，实到董事 7 名。 （五）本次董事会由董事长符杰先生主持，全体高级管理人员列席了会议。 二、董事会会议审议情况 与会董事对提交本次会议的三项议案进行了认真审议，表决情况如下： （一）审议《2025 年半年度报告及摘要》 本 ...

宁夏中科生物科技股份有限公司（以下简称：公司）于 2025 年 6 月 27 日召 开第九届董事会第四十二次会议，审议通过了《关于选举第九届董事会董事长的 议案》，选举符杰先生为公司第九届董事会董事长。根据《公司章程》规定，董 事长为公司法定代表人。公司于近日完成了上述事项的工商变更登记手续，变更 后的《营业执照》基本信息如下： 统一社会信用代码：91640000227694836P 企业名称：宁夏中科生物科技股份有限公司 类 型：股份有限公司（上市、自然人投资或控股） 法定代表人：符杰 证券代码：600165 股票简称：ST 宁科 公告编号：临 2025-086 宁夏中科生物科技股份有限公司 关于公司及子公司完成法人变更并换领营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、公司法人变更情况 注册资本：陆亿捌仟肆佰捌拾捌万叁仟柒佰柒拾伍圆整 成立日期：1998 年 05 月 14 日 住 所：宁夏石嘴山市惠农区河滨街 经营范围：许可项目：肥料生产（依法须经批准的项目，经相关部门批准后 方可开展经营活动）一般 ...

证券代码：600165 股票简称：ST 宁科 公告编号：临 2025-085 宁夏中科生物科技股份有限公司 关于聘任财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》及《宁夏中科生物科技股份有限公司章程》 的相关规定，经宁夏中科生物科技股份有限公司（以下简称：公司）总经理提名， 董事会提名委员会任职资格审查、审计委员会审核通过，公司于 2025 年 7 月 29 日召开第九届董事会第四十三次会议，以 7 票同意、0 票反对、0 票弃权的表决 结果，审议通过了《关于聘任宁夏中科生物科技股份有限公司财务总监的议案》， 聘任金相宇女士（简历附后）为公司财务总监，任期自本次董事会审议通过之日 起至公司第九届董事会届满之日止。 附：财务总监简历 特此公告。 宁夏中科生物科技股份有限公司 董 事 会 二〇二五年七月三十日 1 金相宇女士：1971 年生，中国国籍，无境外永久居留权。大专学历，税务 师，高级会计师。曾任河南利华制药有限公司会计员、财务部经理、资产管理部 财务经理、工会经费审查委员会主 ...

证券代码：600165 证券简称：ST 宁科 公告编号：2025-084 宁夏中科生物科技股份有限公司 关于财务总监离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司 董 事 会 二〇二五年七月二十六日 姓名 离任职务 离任时间 原定任期 到期日 离任原因 是否继续在上 市公司及其控 股子公司任职 具体职务（如适用） 是否存在未 履行完毕的 公开承诺 董春香 财务总监 2025 年 7 月 25 日 2025 年 6 月 30 日注 个人原因 是 公司财务副总监 否 一、提前离任的基本情况 二、离任对公司的影响 根据《中华人民共和国公司法》《公司章程》的有关规定，董春香女士的辞 职报告自送达公司董事会之日起生效。董春香女士将按公司相关规定做好交接工 作，其离任不会影响公司的正常运行。截至本公告披露日，董春香女士未持有公 司股份，不存在未履行完毕的公开承诺。公司董事会将按照法定程序尽快完成新 任财务总监的聘任工作。 公司董事会对董春香女士在担任公司财务总监期间恪尽职守，在公司治理、 资本运作 ...

Transaction Overview - The company approved the transfer of a 10% stake in Ningxia Zhongke Biological New Materials Co., Ltd. from Shizuishan Zhengxingcheng New Materials Technology Partnership for a total consideration of RMB 106 million [1] - The company failed to pay the remaining transfer amount within the stipulated 60 working days, leading to a supplementary agreement allowing payment by October 31, 2022 [2] Debt Settlement Agreement - Due to the outstanding payment, the company was required to pay a penalty of 0.05% per day on the unpaid amount until settled [3] - On November 23, 2023, the company approved a debt settlement agreement using a property as payment for the remaining transfer amount [3] - The company later decided to terminate the debt settlement agreement on December 5, 2023, considering its business development and financial arrangements [3] Property Transfer and Management - The company signed a property holding agreement to ensure the property remains an asset of the company despite the termination of the debt settlement agreement [3] - The company is unable to transfer back the property due to tax payment issues, which are a result of financial constraints [4] - As of the announcement date, the property has been transferred back to the company, and the property holding agreement has been terminated [4][5]

宁夏中科生物科技股份有限公司（以下简称：公司）分别于 2022 年 6 月 15 日、2022 年 7 月 1 日召开第八届董事会第二十三次会议、2022 年第二次临时股 东大会，审议通过了《关于与石嘴山市正兴成新材料技术合伙企业（有限合伙） 签署<宁夏恒力生物新材料有限责任公司股权转让协议>暨关联交易的议案》，石 嘴山市正兴成新材料技术合伙企业（有限合伙）（以下简称：正兴成）将其持有 的宁夏中科生物新材料有限公司（原宁夏恒力生物新材料有限责任公司，以下简 称：中科新材）10%股权转让至公司，转让价款总计人民币 106,000,000 元整， 具体内容详见公司于 2022 年 6 月 16 日披露的《关于与石嘴山市正兴成新材料技 术合伙企业（有限合伙）签署<宁夏恒力生物新材料有限责任公司股权转让协议> 暨关联交易的公告》（公告编号：临 2022-023）。 公司未能在《宁夏恒力生物新材料有限责任公司股权转让协议》（以下简称： 《股权转让协议》）约定的 60 个工作日内向正兴成支付剩余股权转让款。经双方 协商一致，公司于 2022 年 9 月 26 日与正兴成签订了《股权转让协议之补充协议》， 正兴成同意公司在 ...

Core Viewpoint - Ningxia Zhongke Biological Technology Co., Ltd. (*ST Ningke*) is undergoing a pre-restructuring process to address its significant debt issues, with Hunan Chuntou Industrial Development Co., Ltd. stepping in as the lead investor to potentially rescue the company through capital operations and asset injection [2][4][11]. Group 1: Company Crisis - *ST Ningke* has been under severe financial distress, with total debts amounting to 2.236 billion yuan, of which 1.81 billion yuan are overdue debts [4][6]. - The company has faced regulatory penalties for false reporting in its 2022 annual report, resulting in fines totaling 14.95 million yuan for the company and its executives [3][4]. - The company's revenue for 2024 was reported at 345 million yuan, a year-on-year increase of 20.9%, but it still recorded a net loss of 539 million yuan [4][12]. Group 2: Restructuring Efforts - Hunan Chuntou, established in October 2021, has emerged as the primary investor in *ST Ningke*'s restructuring, with its actual controller, Liu Xirong, holding 90% of its shares [11][12]. - The restructuring plan involves a combination of industrial and financial investments, with Hunan Chuntou and 15 financial investors forming a consortium to support the process [11][12]. - If the restructuring is successful, Hunan Chuntou plans to acquire 22.10% of *ST Ningke*'s shares at 1.12 yuan per share, while financial investors will acquire 32.54% at 1.60 yuan per share [13]. Group 3: Future Prospects - The potential integration of Hunan Chuntou's biopharmaceutical assets into *ST Ningke* could significantly alter the company's business model, moving it towards the biopharmaceutical sector [15][17]. - The restructuring must be completed by August 28, 2025, to avoid bankruptcy, creating a tight timeline for the company [16][17]. - Successful restructuring will depend on the effective integration of existing operations and the new biopharmaceutical assets, as well as balancing the exit demands of the financial investors involved [17].

Core Viewpoint - ST Ningke has signed a "Pre-restructuring Investment Agreement" with Hunan Chuantou and other financial investors, marking a significant step in its restructuring process [2][3][4]. Group 1: Pre-restructuring Investment Agreement - The company announced the signing of the "Pre-restructuring Investment Agreement" on July 11, 2024, which is essential for advancing its restructuring efforts [2]. - Two industrial investors submitted restructuring proposals during the recruitment period, with Hunan Chuantou being selected as the main industrial investor [2][4]. - The agreement with Hunan Chuantou and other financial investors is expected to facilitate the smooth progress of the company's pre-restructuring and restructuring work [4]. Group 2: Financial Investors - A list of financial investors has been designated, including companies such as Kaishuo (Hubei) Biotechnology Co., Ltd., National Trust Co., Ltd., and several private equity funds [3]. - These financial investors have also signed the "Pre-restructuring Investment Agreement," indicating their commitment to the restructuring process [3]. Group 3: Legal and Regulatory Context - The signing of the investment agreements is a necessary step in the restructuring process, which will lead to the drafting of a restructuring plan to be submitted for approval by stakeholders [4]. - The company and its management received administrative penalties from the China Securities Regulatory Commission for violations related to false disclosures in the 2022 annual report [5].

Core Viewpoint - Ningxia Zhongke Biological Technology Co., Ltd. has signed a pre-restructuring investment agreement as part of its restructuring process initiated by the Shizuishan Intermediate People's Court, which aims to address the company's financial difficulties and facilitate its recovery [1][2]. Group 1: Pre-restructuring Process - The Shizuishan Intermediate People's Court decided to initiate pre-restructuring for Ningxia Zhongke Biological Technology Co., Ltd. and its subsidiary on May 30, 2024 [1]. - Two industrial investors submitted restructuring investment plans, with Hunan Chuantou Industrial Development Co., Ltd. identified as the main investor [2][5]. - The company has entered into a pre-restructuring investment agreement with both industrial and financial investors to facilitate the restructuring process [3][4]. Group 2: Investment Agreements - The pre-restructuring investment agreement with industrial investors allows them to gain actual control of the company upon successful completion of the restructuring [4]. - Financial investors, including several asset management firms, have also signed pre-restructuring investment agreements, contributing to the restructuring efforts [3][6]. - The agreements are essential for advancing the restructuring process and will be subject to court approval based on the restructuring plan [4][5]. Group 3: Investor Profiles - Hunan Chuantou Industrial Development Co., Ltd. was established in October 2021 with a registered capital of 50 million RMB and focuses on various consulting and technology services [6][7]. - Financial investors include companies like Kaiso (Hubei) Biotechnology Co., Ltd., National Trust Co., Ltd., and others, each with distinct operational focuses and financial backgrounds [8][12][13]. - National Trust Co., Ltd. manages assets totaling approximately 243.39 billion RMB and reported a net profit of 385 million RMB in 2024 [12].